Aion Therapeutic Inc (TSE:AION) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Aion Therapeutic Inc. has acquired the global licensing rights for I2Pure Corp’s patented molecular iodine, aiming to revolutionize water disinfection through Toppen Health’s advanced filtration systems. The new technology will enable the removal of pathogens, PFAS, and pharmaceuticals, promising cleaner water with the help of I2Pure’s slow-release iodine. The deal includes a cash payment and share payments totaling USD $1.25 million.
For further insights into TSE:AION stock, check out TipRanks’ Stock Analysis page.
